Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase.

Narimatsu T, Kambara T, Abe H, Uematsu T, Tokura Y, Suzuki I, Sakamoto K, Takei K, Nishihara D, Nakamura G, Kokubun H, Yuki H, Betsunoh H, Kamai T.

Oncol Lett. 2019 May;17(5):4429-4436. doi: 10.3892/ol.2019.10086. Epub 2019 Feb 28.

2.

Sex steroid hormone receptors in bladder cancer: Usefulness in differential diagnosis and implications in histogenesis of bladder cancer.

Imai Y, Noda S, Matsuyama C, Shimizu A, Kamai T.

Urol Oncol. 2019 Jun;37(6):353.e9-353.e15. doi: 10.1016/j.urolonc.2019.01.023. Epub 2019 Feb 6.

PMID:
30737158
3.

Carbon dioxide insufflation to control intractable bleeding during transurethral resection of bladder tumor.

Kobayashi M, Kamai T.

Indian J Urol. 2019 Jan-Mar;35(1):73-74. doi: 10.4103/iju.IJU_263_18.

4.

Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications.

Kobayashi M, Uematsu T, Tokura Y, Takei K, Sakamoto K, Narimatsu T, Nukui A, Kamai T.

Int Braz J Urol. 2019 Jan-Feb;45(1):169-178. doi: 10.1590/S1677-5538.IBJU.2018.0271.

5.

The Predictive Value of Glycated Hemoglobin and Albumin for the Clinical Course Following Hospitalization of Patients with Febrile Urinary Tract Infection.

Kobayashi M, Uematsu T, Nakamura G, Kokubun H, Mizuno T, Betsunoh H, Kamai T.

Infect Chemother. 2018 Sep;50(3):228-237. doi: 10.3947/ic.2018.50.3.228.

6.

Increased Nrf2 expression by renal cell carcinoma is associated with postoperative chronic kidney disease and an unfavorable prognosis.

Yuki H, Kamai T, Murakami S, Higashi S, Narimatsu T, Kambara T, Betsunoh H, Abe H, Arai K, Shirataki H, Yoshida KI.

Oncotarget. 2018 Jun 19;9(47):28351-28363. doi: 10.18632/oncotarget.25322. eCollection 2018 Jun 19.

7.

Clinically significant association of elevated expression of nuclear factor E2-related factor 2 expression with higher glucose uptake and progression of upper urinary tract cancer.

Nukui A, Narimatsu T, Kambara T, Abe H, Sakamoto S, Yoshida KI, Kamai T.

BMC Cancer. 2018 May 2;18(1):493. doi: 10.1186/s12885-018-4427-1.

8.

A case of giant hemorrhagic hydrocele testis.

Tokura Y, Kobayashi M, Kamai T.

Urol Case Rep. 2018 Mar 3;18:44-45. doi: 10.1016/j.eucr.2018.03.003. eCollection 2018 May. No abstract available.

9.

Feeling of incomplete emptying with little post-void residual in patients with lower urinary tract symptoms: Clinical implications and treatment outcomes.

Kobayashi M, Tokura Y, Kambara T, Nukui A, Kamai T.

Low Urin Tract Symptoms. 2019 Apr;11(2):O59-O64. doi: 10.1111/luts.12217. Epub 2018 Feb 22.

PMID:
29473339
10.

Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma.

Nukui A, Yanai Y, Tsuzuki T, Abe H, Arai K, Yoshida KI, Kamai T.

Oncotarget. 2017 Dec 25;9(3):4188-4199. doi: 10.18632/oncotarget.23683. eCollection 2018 Jan 9.

11.

Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer.

Kamai T, Tokura Y, Uematsu T, Sakamoto K, Suzuki I, Takei K, Narimatsu T, Kambara T, Yuki H, Betsunoh H, Abe H, Fukabori Y, Yashi M, Yoshida KI.

Open Heart. 2018 Jan 3;5(1):e000666. doi: 10.1136/openhrt-2017-000666. eCollection 2018.

12.

Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.

Abe H, Takei K, Uematsu T, Tokura Y, Suzuki I, Sakamoto K, Nishihara D, Yamaguchi Y, Mizuno T, Nukui A, Kobayashi M, Kamai T.

Int J Clin Oncol. 2018 Apr;23(2):338-346. doi: 10.1007/s10147-017-1207-x. Epub 2017 Nov 2.

PMID:
29098519
13.

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α1-Blockers.

Kobayashi M, Nukui A, Kamai T.

Int Neurourol J. 2017 Sep;21(3):197-203. doi: 10.5213/inj.1734830.415. Epub 2017 Sep 12.

14.

[Diagnostic Impact of 3D-CT with Retrograde Pyelography for Ureteropelvic Junction Obstruction : A Case Report].

Takei K, Abe H, Nishihara D, Mizuno T, Tokura Y, Suzuki I, Sakamoto K, Yuki H, Kambara T, Betsunou H, Yashi M, Fukabori Y, Kamai T, Inamura K, Shioyama Y, Kaji Y.

Hinyokika Kiyo. 2017 Jul;63(7):267-270. doi: 10.14989/ActaUrolJap_63_7_267. Japanese.

15.

Case of hydrocele testis caused by vaginalitis, a rare manifestation of immunoglobulin G4-related disease.

Tokura Y, Kobayashi M, Kusakabe T, Kamai T.

Int J Urol. 2017 Oct;24(10):771-773. doi: 10.1111/iju.13430. Epub 2017 Aug 15.

16.

Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.

Yashi M, Nukui A, Tokura Y, Takei K, Suzuki I, Sakamoto K, Yuki H, Kambara T, Betsunoh H, Abe H, Fukabori Y, Nakazato Y, Kaji Y, Kamai T.

BMC Urol. 2017 Jun 23;17(1):47. doi: 10.1186/s12894-017-0238-y.

17.
18.

Extravasation of Urine Associated with Bilateral Complete Ureteral Duplication, Vesicoureteral Reflux and Benign Prostatic Hyperplasia.

Suzuki I, Kaga K, Takei K, Tokura Y, Sakamoto K, Nishihara D, Mizuno T, Yuki H, Betsunoh H, Abe H, Yashi M, Fukabori Y, Yamanishi T, Kamai T.

Urol Case Rep. 2017 Jan 28;11:47-49. doi: 10.1016/j.eucr.2016.12.011. eCollection 2017 Feb.

19.
20.

Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy.

Kobayashi M, Nukui A, Kamai T.

Int J Clin Oncol. 2017 Feb;22(1):174-180. doi: 10.1007/s10147-016-1038-1. Epub 2016 Sep 8.

PMID:
27631094
21.
22.

Update on advances in molecular PET in urological oncology.

Kitajima K, Yamamoto S, Fukushima K, Minamimoto R, Kamai T, Jadvar H.

Jpn J Radiol. 2016 Jul;34(7):470-85. doi: 10.1007/s11604-016-0553-3. Epub 2016 May 24. Review.

23.

Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.

Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S.

Cancer Sci. 2016 Jul;107(7):1013-7. doi: 10.1111/cas.12951. Epub 2016 Jun 14.

24.
25.

Abnormal 18F-FDG uptakes in the prostate due to two different conditions of urine reflux: a mimicker of prostate cancer.

Inamura K, Kaji Y, Sakamoto S, Masuda A, Kamai T.

Springerplus. 2016 Jan 20;5:46. doi: 10.1186/s40064-016-1696-5. eCollection 2016.

26.

A Rare Complication of Chylous Leakage After Open Partial Nephrectomy Successfully Resolved by Somatostatin Analogue.

Kobayashi M, Kambara T, Kamai T.

Urol Case Rep. 2015 Sep 11;3(6):195-7. doi: 10.1016/j.eucr.2015.08.006. eCollection 2015 Nov.

27.

Swimming Motility Reduces Deposition to Silica Surfaces.

Lu N, Massoudieh A, Liang X, Hu D, Kamai T, Ginn TR, Zilles JL, Nguyen TH.

J Environ Qual. 2015 Sep;44(5):1366-75. doi: 10.2134/jeq2015.03.0141.

PMID:
26436254
28.

Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?

Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T, Uchiyama T.

Int J Urol. 2015 Dec;22(12):1143-8. doi: 10.1111/iju.12915. Epub 2015 Aug 27.

29.

The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia.

Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T, Uchiyama T.

J Pharmacol Sci. 2015 Jun;128(2):65-70. doi: 10.1016/j.jphs.2015.05.005. Epub 2015 May 27.

30.

Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer.

Mizuno T, Kamai T, Abe H, Sakamoto S, Kitajima K, Nishihara D, Yuki H, Kambara T, Betsunoh H, Yashi M, Fukabori Y, Kaji Y, Yoshida K.

BMC Cancer. 2015;15:1097. doi: 10.1186/s12885-015-1097-0. Epub 2015 Mar 10.

31.

Information of prostate biopsy positive core: does it affect MR detection of prostate cancer on using 3T-MRI?

Yoshida R, Kaji Y, Tamaki Y, Katsube T, Kitagaki H, Kanbara T, Kamai T.

Jpn J Radiol. 2015 May;33(5):246-52. doi: 10.1007/s11604-015-0407-4. Epub 2015 Mar 12.

PMID:
25761402
32.

Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer.

Muto S, Abe H, Noguchi T, Sugiura S, Kitamura K, Isotani S, Ide H, Yamaguchi R, Kamai T, Horie S.

Int J Urol. 2015 May;22(5):490-4. doi: 10.1111/iju.12727. Epub 2015 Feb 28.

33.

Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma.

Masuda A, Arai K, Nishihara D, Mizuno T, Yuki H, Kambara T, Betsunoh H, Abe H, Yashi M, Fukabori Y, Yoshida K, Kamai T.

Biomed Res Int. 2014;2014:396064. doi: 10.1155/2014/396064. Epub 2014 Jun 25.

34.

The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells.

Abe H, Kamai T, Hayashi K, Anzai N, Shirataki H, Mizuno T, Yamaguchi Y, Masuda A, Yuki H, Betsunoh H, Yashi M, Fukabori Y, Yoshida K.

BMC Cancer. 2014 Jun 7;14:412. doi: 10.1186/1471-2407-14-412.

35.

Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsy.

Yashi M, Mizuno T, Yuki H, Masuda A, Kambara T, Betsunoh H, Abe H, Fukabori Y, Muraishi O, Suzuki K, Nakazato Y, Kamai T.

BMC Urol. 2014 May 29;14:43. doi: 10.1186/1471-2490-14-43.

36.

Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.

Yashi M, Nishihara D, Mizuno T, Yuki H, Masuda A, Kambara T, Betsunoh H, Abe H, Fukabori Y, Muraishi O, Kamai T.

Clin Genitourin Cancer. 2014 Oct;12(5):e197-203. doi: 10.1016/j.clgc.2014.02.007. Epub 2014 Mar 2.

PMID:
24674784
37.

LAT1 is a central transporter of essential amino acids in human umbilical vein endothelial cells.

Hayashi K, Jutabha P, Kamai T, Endou H, Anzai N.

J Pharmacol Sci. 2014;124(4):511-3. Epub 2014 Mar 27.

38.

Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report.

Yuki H, Kamai T, Kubota K, Abe H, Nishihara D, Mizuno T, Masuda A, Betsunoh H, Yashi M, Fukabori Y, Yoshida K.

Onco Targets Ther. 2014 Feb 15;7:289-95. doi: 10.2147/OTT.S58089. eCollection 2014.

39.

Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma.

Betsunoh H, Fukuda T, Anzai N, Nishihara D, Mizuno T, Yuki H, Masuda A, Yamaguchi Y, Abe H, Yashi M, Fukabori Y, Yoshida K, Kamai T.

BMC Cancer. 2013 Oct 30;13:509. doi: 10.1186/1471-2407-13-509.

40.

Nocturia Quality-of-Life questionnaire is a useful tool to predict nocturia and a risk of falling in Japanese outpatients: a cross-sectional survey.

Yamanishi T, Fuse M, Yamaguchi C, Uchiyama T, Kamai T, Kurokawa S, Morita T.

Int J Urol. 2014 Mar;21(3):289-93. doi: 10.1111/iju.12242. Epub 2013 Aug 29.

41.

Comment on "extending applicability of correlation equations to predict colloidal retention in porous media at low fluid velocity".

Nelson KE, Ginn TR, Kamai T.

Environ Sci Technol. 2013 Jul 16;47(14):8078-9; discussion 8080-1. doi: 10.1021/es401944q. Epub 2013 Jun 26. No abstract available.

PMID:
23777307
42.

Recent advances in the treatment of metastatic renal cell carcinoma.

Abe H, Kamai T.

Int J Urol. 2013 Oct;20(10):944-55. doi: 10.1111/iju.12187. Epub 2013 May 21. Review.

43.

Broader perspective on ecosystem sustainability: consequences for decision making.

Sidle RC, Benson WH, Carriger JF, Kamai T.

Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9201-8. doi: 10.1073/pnas.1302328110. Epub 2013 May 17.

44.

Randomized, Single-Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propiverine in the Treatment of Overactive Bladder.

Fukuda T, Yamanishi T, Uchiyama T, Kamai T.

Low Urin Tract Symptoms. 2013 Jan;5(1):11-6. doi: 10.1111/j.1757-5672.2012.00157.x. Epub 2012 May 9.

PMID:
26663242
45.
46.

Renal metanephric adenoma mimicking papillary renal cell carcinoma on computed tomography: a case report.

Masuda A, Kamai T, Mizuno T, Kambara T, Abe H, Tomita S, Fukabori Y, Yamanishi T, Kaji Y, Yoshida K.

Urol Int. 2013;90(3):369-72. doi: 10.1159/000341940. Epub 2012 Oct 17.

PMID:
23076029
47.

STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.

Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S; Japan Immunotherapy SNPs-Study Group for Kidney Cancer.

Eur Urol. 2013 Apr;63(4):745-52. doi: 10.1016/j.eururo.2012.09.052. Epub 2012 Sep 28.

PMID:
23063454
48.

A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma.

Shinohara N, Nonomura K, Abe T, Maruyama S, Kamai T, Takahashi M, Tatsugami K, Yokoi S, Deguchi T, Kanayama H, Oba K, Naito S.

Cancer Sci. 2012 Sep;103(9):1695-700. doi: 10.1111/j.1349-7006.2012.02351.x. Epub 2012 Jul 11. Erratum in: Cancer Sci. 2012 Oct;103(10):1905.

49.

Oncocytic carcinoid of the kidney positively detected by I-131 MIBG scintigraphy.

Tamaki Y, Hashimoto T, Kamai T, Honma K, Ejima Y, Yamazaki E, Yoshida R, Arakawa H, Kuwashima S, Kaji Y, Sasaki R, Sugimura K.

Clin Nucl Med. 2011 Nov;36(11):1025-8. doi: 10.1097/RLU.0b013e3182291a44. No abstract available.

PMID:
21975394
50.

Increased alpha-taxilin protein expression is associated with the metastatic and invasive potential of renal cell cancer.

Mashidori T, Shirataki H, Kamai T, Nakamura F, Yoshida K.

Biomed Res. 2011 Apr;32(2):103-10.

Supplemental Content

Support Center